Close

LRRFIP2

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

LRRFIP2, along with MYD88, binds to the cytosolic tail of toll-like receptor 4 (TLR4), which causes activation of nuclear factor kappa B signaling. The ubiquitin-like protein FAT10 prevents the interaction of the encoded protein and TLR4, thereby inactivating the nuclear factor kappa B signaling pathway. In addition, LRRFIP2 can downregulate the NLRP3 inflammasome by recruiting the caspase-1 inhibitor Flightless-I to the inflammasome complex.
  • CAR Vector Products

  • DMAb

Loading...
  • Target Species:
  • Antibody Clone:
  • Antibody Host:
  • Receptor Construction:
  • Vector Type:
  • Targeting Cell Type:
CAT Product Name Target Species Antibody Clone Antibody Host Receptor Construction Vector Type Targeting Cell Type CAR Vector Type Inquiry & Datasheet
CAR-YJ142 Anti-LRRFIP2 (377C3a) h(41BB-CD3ζ) CAR, pCDCAR1 Human 377C3a Mouse scFv-41BB-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-YJ642 Anti-LRRFIP2 (377C3a) h(CD28-CD3ζ) CAR, pCDCAR1 Human 377C3a Mouse scFv-CD28-CD3ζ Lentiviral vector T cell   Add to Cart   Datasheet
CAR-0320ZP1449 Anti-LRRFIP2 (488D4b) h(CD28-CD3ζ) CAR, pCDCAR1 Human 488D4b Mouse scFv-CD28-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
CAR-0320ZP1450 Anti-LRRFIP2 (488D4b) h(4-1BB-CD3ζ) CAR, pCDCAR1 Human 488D4b Mouse scFv-4-1BB-CD3ζ Lentiviral vector T Cell   Add to Cart   Datasheet
Unable to find the desired product? Explore the Filter Options at the top of the list.
Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.